Paper No	_
Date Filed: November 18, 2016	<b>,</b>

#### Filed On Behalf Of:

Novartis AG

By:

Nicholas N. Kallas NKallas@fchs.com ZortressAfinitorIPR@fchs.com (212) 218-2100

#### UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.,

Petitioner,

v.

NOVARTIS AG,

Patent Owner.

Case IPR2016-01479

Patent No. 9,006,224

PATENT OWNER'S PRELIMINARY RESPONSE UNDER 37 C.F.R. § 42.107




## TABLE OF CONTENTS

I.	Introduction1				
II.	The Person Of Ordinary Skill In The Art And Invention Date				
III.	Background On Neuroendocrine Tumors, Including Advanced PNETs				
IV.	Clair	Claim Construction			
	A.	"Advanced" Tumors Are "Metastatic Or Unresectable"	7		
	В.	The Ordinary And Customary Meaning Of "Advanced" Is Not "After Failure Of Cytotoxic Chemotherapy"	9		
V.	The Board Should Deny Grounds 3 And 4 Because No Reference Teaches Or Suggests The Claim Element "Advanced [PNETs] After Failure Of Cytotoxic Chemotherapy"				
	A.	Boulay 2004	12		
	B.	O'Donnell	14		
	C.	Duran	15		
	D.	Tabernero	17		
VI.	The Board Should Deny Grounds 1-4 Because One Of Ordinary Skill Would Not Have Had A Reasonable Expectation That Everolimus Would Effectively Treat "Advanced [PNETs] After Failure Of Cytotoxic Chemotherapy"				
	A.	Par's Reasonable Expectation Of Success Arguments Ignore That Tumors That Had Failed Cytotoxic Chemotherapy Generally Were More Resistant To			
		Treatment And More Difficult To Treat	20		



	В.	The Art Cited In Grounds 1 And 2 Fails To Establish A Reasonable Expectation That Everolimus Would Be Effective In A Method Of Treating "Advanced [PNETs]			
		Afte	r Failure Of Cytotoxic Chemotherapy"	23	
		1.	Oberg 2004	24	
		2.	Boulay 2004	25	
		3.	O'Donnell	26	
		4.	Tabernero	29	
	C.	Estal Wou	Art Cited In Par's Grounds 3 And 4 Fail To blish A Reasonable Expectation That Everolimus ald Be Effective In A Method Of Treating "Advanced ETs] After Failure Of Cytotoxic Chemotherapy"	33	
		1.	Boulay 2004, O'Donnell And Tabernero	34	
		2.	Duran	34	
		3.	Additional Art Referenced In Connection With Grounds 3 And 4	38	
VII.	The Methods Of Claims 1-3 Of The '224 Patent Have Demonstrated Unexpected Results			40	
VIII	Conc	lucion		15	



## TABLE OF AUTHORITIES

### **Cases**

10X Genomics, Inc. v. Univ. of Chicago,	
IPR2015-01163 (Patent Tr. & App. Bd. Nov. 16, 2015), Paper 14	20, 23
Ashland Oil, Inc. v. Delta Resins & Refractories, Inc., 776 F.2d 281 (Fed. Cir. 1985)	22, 36
Coalition for Affordable Drugs V LLC v. Hoffman-LaRoche Inc., IPR2015-01792 (Patent Tr. & App. Bd. March 11, 2016), Paper 14	40, 45
Cuozzo Speed Techs., LLC v. Lee, 136 S. Ct. 2131 (2016)	7
In re Translogic Tech., Inc., 504 F.3d 1249 (Fed. Cir. 2007)	7
InSite Vision Inc. v. Sandoz, Inc., 783 F.3d 853 (Fed. Cir. 2015)	20, 23
IntelGenX Corp. v. ICOS Corp., IPR2016-00678 (Patent Tr. & App. Bd. Sept. 1, 2016), Paper 13	12
Janssen Pharmaceutica, N.V. v. Eon Labs. Mfg., Inc., 134 Fed. Appx. 425 (Fed. Cir. 2005)	9
Johns Manville Corp. v. Knauf Insulation, Inc., IPR2015-01633 (Patent Tr. & App. Bd. Jan. 4, 2016), Paper 10	22, 36
NetApp Inc. v. Crossroads Sys., Inc., IPR2014-01233, 2015 WL 996342 (Patent Tr. & App. Bd. Feb. 10, 2015)	11
Par Pharm., Inc. v. Novartis AG, IPR2016-00078, 2016 WL 2849201 (Patent Tr. & App. Bd. Apr. 28, 2016)	12



Praxair Distrib., Inc. v. INO Therapeutics, Inc., IPR2015-00522, -00524, -00525, -00526 (Patent Tr. & App. Bd. July 29, 2015), Paper 12	
Regulations	
37 C.F.R. § 42.100(b)	7
37 C.F.R. § 42.104(b)(4)	2, 11, 12, 19
37 C.F.R. § 42.65(a)	22, 36



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

